Gastrointestinal Cancer

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses sequencing therapy for patients with hepatocellular carcinoma.

The European Commission has approved lenvatinib (Lenvima) as a first-line treatment for adult patients with advanced or unresectable hepatocellular carcinoma.

Michael J. Overman, MD, discusses the current state of immunotherapy in patients with CRC and how to optimally manage immune-related adverse events.

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses molecular testing in gastrointestinal cancers.

Scott Paulson, MD, discusses recent updates in the treatment of patients with neuroendocrine tumors.

Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses when to consider using Lutathera (lutetium Lu 177 dotatate) in patients with neuroendocrine tumors (NETs).

A. David McCollum, MD, oncologist, Baylor University Medical Center, discusses frontline therapy for patients with metastatic colorectal cancer (mCRC).

Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses regorafenib (Stivarga) dosing in the treatment of patients with metastatic colorectal cancer.

John L. Cameron, MD, is most commonly associated with the refinement of Whipple procedures; these extensive surgical operations became far more successful thanks to his dedication.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the FDA approval of lenvatinib (Lenvima) as a frontline systemic treatment for patients with advanced hepatocellular carcinoma (HCC).

The FDA has approved lenvatinib as a first-line treatment for patients with unresectable hepatocellular carcinoma.

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses biomarker-driven strategies in gastric and gastroesophageal junction (GEJ) cancers.

Jodie Barr, DO, discusses the evolution of treatment of patients with neuroendocrine tumors and the need for biomarkers.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the evolution of treatment for patients with pancreatic cancer.

The PD-L1 immunohistochemistry 22C3 pharmDx can be an aid in identifying patients with non–small cell lung cancer and gastrointestinal cancers who are eligible for pembrolizumab (Keytruda) monotherapy.

Cathy Eng, MD, highlights recent data that could shape the treatment landscape for several gastrointestinal cancers.

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the BRIGHTER study in patients with gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Todd A. Yezefski, MD, senior fellow, Fred Hutchinson Cancer Research Center, University of Washington, discusses the differences between colorectal cancer care costs in the Unites States and Canada.

Manish A. Shah, MD, shares insight on the challenges that remain in the treatment of esophageal and gastric cancers.

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses sequencing therapy for patients with hepatocellular carcinoma.

The FDA has granted a breakthrough therapy designation to the combination of encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) for the treatment of patients with BRAF V600E–mutant metastatic colorectal cancer.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, reflects on the findings from the ReDOS study in patients with metastatic colorectal cancer.

Susanna Ulahannan, MD, highlights trials from the 2018 ASCO Annual Meeting across gastrointestinal malignancies and future therapeutic approaches across the landscape.

Susanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses the phase II PRODIGE 35/PANOPTIMOX trial in pancreatic cancer.

Thierry Conroy, MD, medical oncologist, director, Institut de Cancerologie de Lorraine, discusses the findings with an adjuvant a modified FOLFIRINOX regimen in patients with nonmetastatic pancreatic ductal adenocarcinoma.